Death rates after first heart attack have gone down for those without diabetes or with type 2 diabetes, but not type 1

heart attack

Credit: CC0 Public Domain

New research to be presented at this year’s Annual Meeting of the European Association for the Study of Diabetes (EASD) in Hamburg, Germany (2–6 October) shows that following a heart attack, there have been falls in the death rates of both people without diabetes and those with type 2 diabetes, but not those with type 1 diabetes. The study is by Dr. Linn Glynn, Karolinska Institutet, Stockholm, Sweden, and colleagues.

Earlier studies have demonstrated that people with diabetes have a worse outcome after attacks ( [MI]), compared to people without diabetes. In contrast, recent studies have shown a substantially decline in overall mortality and cardiovascular (CV) outcome among people with diabetes. However, trends in survival after a first in people with diabetes and without diabetes have still not been extensively studied.

Using data from between 2006 to 2020, the authors identified 2,527 individuals with type 1 diabetes (T1D), 48,321 individuals with type 2 diabetes (T2D) and 243,170 individuals without diabetes with a in national health care registries. The outcomes measured were trends in survival, (overall mortality and cardiovascular [CV] ), and major cardiovascular events (MACE), meaning the combined outcomes of non-fatal stroke, non-fatal MI, CV death and hospitalized heart failure. Computer and statistical modeling was used to establish any variations in these outcomes.

Individuals with T1D were younger (62 years) and more often women (44%) compared to individuals with T2D (75 years,) women (38%), and to the without diabetes (73 years) women (38%). Three-year trends in death, CV death and MACE between groups are shown in the full abstract.

During follow-up and after multiple adjustments (sex, age, comorbidities, socioeconomic factors and medication) there was a significant decreased annual incidence trend for all cause death in control group (-1.9% per year) and individuals with T2D (-1.3% per year) with no such trend in individuals with T1D (no change). Corresponding numbers for CV death were for control group -2.0% per year, T2D -1.6% year, and T1D -0.5% per year, but the result for T1D was not statistically significant. For MACE, incidence in the control group fell by 2.3% per year, T2D by 1.9% per year and T1D by 0.6% per year, but again the result for T1D was not statistically significant.

Discussing potential reasons for the findings, the authors say that the standard care following a heart attack has improved with more availability of—for example—percutaneous coronary intervention and better overall medical treatment. However, this standard of care should have improved in all three groups.

In this study population, the authors say that people with T1D had a longer duration of diabetes and a higher mean glycated hemoglobin (a measure of the average blood sugar level over the past 3 months) than people with T2D, which might have an impact on the risk of developing a heart attack as well as the prognosis following a heart attack.

The authors conclude, “During the last 15 years, the risk of death and major cardiovascular events in people without diabetes and with type 2 diabetes after having a first-time heart attack has decreased significantly. In contrast, this decreasing trend was absent in people with type 1 . Our study highlights the urgent need for understanding the cardiovascular risk in people with T1D.”

Citation:
Death rates after first heart attack have gone down for those without diabetes or with type 2 diabetes, but not type 1 (2023, September 12)
retrieved 6 November 2023
from https://medicalxpress.com/news/2023-09-death-heart-diabetes.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.

Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
One dead in Austria as EU is hit by Salmonella outbreaks thumbnail

One dead in Austria as EU is hit by Salmonella outbreaks

Three Salmonella outbreaks in Austria have been linked to chicken meat from Poland. A total of 27 people have fallen sick and one has died in the trio of Salmonella Enteritidis incidents. Investigation of the outbreaks is being carried out by the Austrian Agency for Health and Food Safety (AGES), the Ministry of Health and
Read More
Women With MS Less Likely to Receive Treatment Than Men thumbnail

Women With MS Less Likely to Receive Treatment Than Men

Meeting Coverage > ECTRIMS — Is "therapeutic inertia" to blame? by Judy George, Deputy Managing Editor, MedPage Today September 21, 2024 Women were less likely than men to be treated for relapsing multiple sclerosis (MS), French registry data showed. Women had a lower probability of receiving any disease-modifying treatment (DMT) and were even less likely
Read More
[New Book] The French Revolution's Terror Boat, etc. thumbnail

[New Book] The French Revolution's Terror Boat, etc.

프랑스 혁명의 공포정(휴 고프, 주명철 옮김, 여문책, 2만원)=아일랜드의 프랑스혁명사 연구자가 프랑스혁명 기간 약 18개월간 이어진 ‘공포정’을 분석한 학술서. 저자는 공포정을 “협박, 대량 체포, 처형으로 민간인을 두렵게 만들고 마음대로 통제하면서 특정한 목적을 달성하려는 체제”라고 설명한다. 저자는 공포정을 탄압과 중앙집권으로만 조명하지 말고, 새로운 사회질서를 수립하려 한 측면도 함께 들여다볼 필요가 있다고 주장한다. 기묘한 중국사(왕레이(王磊), 고상희 옮김, 에쎄,…
Read More
Ongoing COVID-19 pandemic in the Americas threatens growth and development of children, says PAHO Director thumbnail

Ongoing COVID-19 pandemic in the Americas threatens growth and development of children, says PAHO Director

Millions miss out on routine care, including vaccination. Educational crisis also impacts their social, mental, and physical wellbeing. Washington D.C. January 26 (PAHO) – As the COVID-19 outbreak reaches its third year in the Americas, millions of children are missing out on routine vaccinations, putting countries at risk of losing two decades of immunization progress,…
Read More
Study: Children With Alopecia Areata Respond to Tofacitinib thumbnail

Study: Children With Alopecia Areata Respond to Tofacitinib

Oral tofacitinib (Xeljanz), a JAK inhibitor, helped regrow hair in three quarters of pediatric patients with alopecia areata (AA) in a small study conducted at the University of Colorado and published in Pediatric Dermatology. The 11 pediatric patients, ages 8 to 18 years, all with a diagnosis of AA, were treated with tofacitinib. Eight patients,…
Read More
Index Of News
Total
0
Share